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Introduction
Neuroendocrine tumors (NETs) are rare tumors that origi-
nate in cells of neuroendocrine lineage. NETs are classified 
pathologically by their grade as well as their differentia-
tion; therefore, the tumor types within this lineage range 
from low to high grade but also from well differentiated to 
poorly differentiated.1 High-grade neuroendocrine neo-
plasms, in particular, are a group of heterogeneous malig-
nancies that can originate in any part of the body. Large cell 
neuroendocrine carcinoma (LCNEC) is an aggressive sub-
type of high-grade neuroendocrine neoplasm. The most 
common site of origin for LCNEC is the thorax; however, 
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it has been reported in the gastrointestinal tract, biliary 
tract, urogenital region, head, neck and the gynecologic 
tract among others. Diagnosis depends on a definite pathol-
ogy because prognosis and treatment varies drastically 
between LCNEC and well-differentiated neuroendocrine 
tumors. LCNEC pathology is characterized by an organoid, 
trabecular, or cordlike growth pattern interspersed by 
peripheral palisading, rosette clusters, and geographic 
necrosis.2 There is also a high mitotic rate with a predomi-
nance of large cells with large vesicular nuclei and promi-
nent nucleoli.2 The growth pattern for LCNEC follows 
peripheral palisading and necrosis to a variable extent. 
LCNEC is usually argyrophilic and normally shows posi-
tive reactivity for synaptophysin, CD56, or chromogranin.3 
Chromogranin is a sensitive and specific serum marker for 
low-grade neuroendocrine tumors, however its utility is 
limited in high-grade neuroendocrine carcinomas (NEC).4 
Anecdotal reports suggest that neuron-specific enolase is a 
sensitive tumor marker for LCNEC and other high-grade 
NEC, however NET/NEC serum tumor markers suffer 
from lack of specificity and high variability and cannot be 
considered diagnostic.5 Furthermore, adenocarcinoma, 
squamous cell carcinoma or small cell carcinoma can coex-
ist with LCNECs.6 As there are many cell types in the 
female gynecologic tract, this large cell pathology is often 
misdiagnosed. Regarding the prevalence of human papil-
loma virus (HPV) in gynecologic LCNEC, the presence of 
HPV has been demonstrated in most reported cases of 
LCNEC, ranging from 53% to 100% with the most com-
mon strains of virus being HPV16 and HPV18.7
This manuscript provides a detailed review of published 
literature on LCNEC of gynecological origin. We discuss 
the results and provide a management strategy for these 
very rare malignancies.
Methods
We performed a PubMed search for material available on 
gynecologic LCNEC. Search words included: “manage-
ment of large cell neuroendocrine carcinoma” and “large 
cell neuroendocrine carcinoma,” which resulted in 181 and 
1969 publications, respectively. After additional filtering 
using the terms “gynecologic,” “cervix,” “ovary” and 
“uterus,” 53 publications were reviewed. Of these, 29 perti-
nent manuscripts were identified for detailed review after 
removal of manuscripts not discussing case reports or not 
including relevant information necessary for this review.
Results
Cervical LCNEC: A total of 45 cases of cervical LCNEC 
were identified, with a median age of 36 years (range 21–
75 years). Our summary of cervical LCNEC is reported in 
Table 1. The median age at presentation was 36 years (range 
21–75). Patients were staged I (51%), II (22%), III (9%), 
and IV (9%), therefore most were early stage. The remain-
ing four patients (9%) did not have a stage identified. Of the 
45 patients, 76% received surgery management, with most 
receiving either radical or total abdominal hysterectomy. In 
this cohort, 69% of patients received systemic platinum-
based chemotherapy and 47% of patients received radiation 
therapy. Outcomes varied significantly. Mortality related to 
cervical LCNEC was reported as 47% at the time of publi-
cation. Survival ranged from 2 weeks post-operative to 
44 months. Median overall survival (OS) was 16 months; 
per stage median survival was 18.5, 12, 21, and 1 month for 
stages I, II, III, and IV, respectively. For the stage III dis-
ease cohort, Tangjitgamol et al. reported a case with a 
44-month survival, thus explaining the increased survival.8 
Survival ranged from 0.5 to 151 months (no survival data 
was available for 11% of patients).
Ovarian LCNEC: We identified 45 unique ovarian 
LCNEC cases in the published literature, and these are sum-
marized in Table 2. The median age at presentation was 
54 years. Epithelial components that were associated with 
these malignancies included mucinous borderline tumor, 
mucinous adenocarcinoma, mucinous adenoma/cystade-
noma, endometrioid adenocarcinoma and those with mixed 
or otherwise unspecified features. The majority of ovarian 
LCNECs were unilateral. Most patients were diagnosed at 
an early stage with stages I, II, III, and IV at 33%, 7%, 22%, 
and 24%, respectively. The remaining six patients did not 
have a stage reported. Of significance, all patients received 
surgery and 87% also received chemotherapy. In this cohort, 
of the 39 patients that received some form of chemotherapy; 
34 received platinum-based therapy and the remaining five 
did not specify the form of chemotherapy. At publication, 
56% of patients had died of the disease. Median overall sur-
vival was 8 months; stratified OS for stages I to IV was 9.5, 
22.5 (n = 3 for this group), 8 and 8 months, respectively. 
Outcome data was not available for two patients. Stage II 
disease represents 3 of the 45 cases; survival of one case 
was not available. Oshita et al. reported a survival of 
40 months in one patient with stage II disease, thus explain-
ing the increased median survival of this cohort.9 Of all the 
patients, survival ranged from 0 to 68 months.
Uterine/Vaginal LCNEC: We found 13 LCNEC cases of 
uterine origin as described in Table 3; 12 of the 13 were 
endometrial in origin and the remaining one was of uterine 
corpus origin. Median age at presentation was 71 years. 
Unlike previous cohorts, the majority of patients presented 
with stage III/IV disease. The percentage among stages 
I-IV were 31%, 8%, 38%, and 23%, respectively. 12 
patients (92%) received surgery and 6 (46%) received 
chemotherapy. For the patients that received chemotherapy, 
a platinum-based therapy was employed in all cases; three 
patients received carboplatin plus etoposide, two patients 
received cisplatin+irinotecan, and one patient received 
carboplatin+paclitaxel. In this cohort, 6 of 13 patients 
received radiation therapy. The percentage of patients with 
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Table 1. Cervical large cell neuroendocrine carcinomas reported in the literature.
Origin Presentation Age Stage Surgery Treatment Response (duration) Authors 
(Reference)
Cervix Post-fibroid 
myomectomy 
surgery
48 IV None RT, nivolumab + sandostatin AWD (12 months) Shahabi et al.4
Cervix Routine 
screening
27 IA Radical 
abdominal 
trachelectomy, 
PLD
Cisplatin + etoposide NED (6 months) Rajkumar25
Cervix N/A 30 IIB None RT and brachytherapy; 
Etoposide + cisplatin
NED (23 months) Li26
Cervix Vaginal bleeding 31 IB TAH, BSO RT, chemo AWD (151 months) Sato et al.17
Cervix Vaginal bleeding 34 IB TAH, BSO RT, chemo DOD (19 months) Sato et al.17
Cervix Vaginal bleeding 27 IB TAH, BSO RT, chemo DOD (16 months) Sato et al.17
Cervix Vaginal bleeding 51 IB TAH, BSO RT, chemo DOD (16 months) Sato et al.17
Cervix Abnormal Pap 47 IB TAH, BSO RT, chemo NED (12 months) Sato et al.17
Cervix Abnormal Pap 42 IIA TAH, BSO RT, chemo DOD (6 months) Sato et al.17
Cervix N/A 31 IA RH NFT NED (10 months) Yun27
Cervix Atypical vaginal 
bleeding
40 IB TAH, BSO, PLD NFT NED (9 months) Kawauchi28
Cervix Vaginal spotting 47 IIA RH, PPALD RT and brachytherapy (patient 
could not afford chemo)
NED (6 months) Cetiner et al.12
Cervix Screening Pap 25 IB1 RH, PPALD INITIAL: Etoposide + cisplatin; 
RECURRENCE: Vincristine, 
adriamycin + cytoxan; 
carboplatin + etoposide; 
THEN: Topotecan; THEN: 
Paclitaxel; THEN: Protein 
kinase C inhibitor
Initial partial 
response then 
DOD (35 months)
Krivak et al.15
Cervix Post-coital 
bleeding
36 IIA None RT, concurrent 
etoposide + cisplatin
Progression, DOD 
(33 months)
Krivak et al.15
Cervix Vaginal bleeding 
most common
55 IIB None NFT AWD (1 months) Rhemtula29
Cervix N/A 75 IIIB None RT DOD (3 months) Rhemtula29
Cervix N/A 51 IVB None NFT DOD (0.5 months) Rhemtula29
Cervix N/A 65 IVB None RT DOD (1 months) Rhemtula29
Cervix N/A 42 N/A None NFT N/A Rhemtula29
Cervix Vaginal bleeding 51 IIA2 RH, BSO, 
bilateral PLD
Irinotecan + cisplatin prior to 
surgery cisplatin
NED (21 months) Omori et al.7
Cervix Post-coital 
bleeding
31 N/A RH Cisplatin + irinotecan NED (15 months) Tanimoto30
Cervix 6 week post-
partum check
33 IB RH, BSO, 
PPALD
Cisplatin + etoposide NED (24 months) Yoseph31
Cervix N/A 37 IIIB Unknown Unknown DOD (21 months) Kajiwara 
et al.18
Cervix N/A 55 IIA Unknown Unknown DOD (12 months) Kajiwara 
et al.18
Cervix N/A 38 IB TAH, BSO Chemo + radio-chemo AWD (21 months) Baykal32
Cervix Pelvic pain and 
vaginal bleeding
31 IIIB TAH, BSO, 
PPALD
Chemo, RT N/A Powell33
Cervix N/A 60 N/A RH Chemo, RT DOD (18 months) Markapoulos34
Cervix N/A 40 IVB None Platinum based chemo N/A Brown35
Cervix Abnormal Pap 24 IB2 TAH Concurrent cisplatin + RT;  
THEN: Etoposide + cisplatin +  
doxorubicin; THEN: Oral  
etoposide; Brachytherapy also 
used
NED (47 months) Embry et al.14
(Continued)
4 Rare Tumors
Origin Presentation Age Stage Surgery Treatment Response (duration) Authors 
(Reference)
Cervix Abnormal Pap 36 IA2 RH NFT NED (36 months) Gilks et al.16
Cervix Abnormal Pap 35 IB RH Etoposide + cisplatin + RT DOD (18 months) Gilks et al.16
Cervix Abnormal Pap 33 IB RH Chemo DOD (8 months) Gilks et al.16
Cervix Vaginal bleeding 31 IB RH Chemo NED (36 months) Gilks et al.16
Cervix Vaginal bleeding 62 IIA RH NFT DOD (6 months) Gilks et al.16
Cervix Vaginal bleeding 38 IA2 RH N/A LFU Gilks et al.16
Cervix Vaginal bleeding 31 IB RH Adriamycin, vincristine, 
cyclophosphamide
DOD (12 months) Gilks et al.16
Cervix N/A 29 IB RH NFT DOD (24 months) Gilks et al.16
Cervix N/A 36 IB RH Cisplatin, etoposide, RT DOD (24 months) Gilks et al.16
Cervix N/A 21 IB RH Cisplatin, etoposide, 
adriamycin
DOD (10 months) Gilks et al.16
Cervix N/A 29 IB RH Cisplatin, etoposide, 
adriamycin
NED (30 months) Gilks et al.16
Cervix N/A 25 IB RH Carboplatin, etoposide NED (6 months) Gilks et al.16
Cervix Vaginal bleeding 37 N/A RH Chemo, RT N/A Niwa36
Cervix N/A 42 III Extrafascial 
hysterectomy, 
BSO, and partial 
OMY
Paclitaxel + carboplatin 
(patient declined RT); 
RECURRENCE: Re-induction 
paclitaxel carboplatin, then 
cisplatin and etoposide
DOD (44 months) Tangjitgamol 
et al.8
Cervix Abnormal Pap 45 IIB RH, BSO and 
PLD
RT, brachytherapy, and 
concurrent cisplatin
NED (unknown) Dikmen37
Cervix Post-coital 
vaginal bleeding
35 IIB TAH, RSO Cyclophosphamide, 
adriamycin, cytoxan, cisplatin, 
etoposide, RT adjuvant therapy 
with ifosfamide, cisplatin, and 
etoposide
DOD (19 months) Tsou et al.1
AWD: alive with disease; BSO: bilateral salpingo-oophorectomy; Chemo: non-specified chemotherapy; DOD: dead of disease; LFU: lost to follow 
up; N/A: not available; NED: no evidence of disease; NFT: no further treatment; OMY: omenectomy; PLD: pelvic lymph node dissection; PPALD: 
pelvic and para-aortic lymph node dissection; RH: radical hysterectomy; RSO: right salpingo-oophorectomy; RT: radiation therapy; TAH: total 
abdominal hysterectomy.
Table 1. (Continued)
uterine LCNEC that died of disease was 46%. Median OS 
was 7.5, 23 (n = 1), 10 and 1 month for stages I-IV, respec-
tively, with survival ranging from 1 month to 23 months. 
Jin et al. reported one case of a 53-year-old female that was 
diagnosed with stage IV vaginal LCNEC. She was treated 
with palliative chemotherapy and radiation and was alive 
with disease at 12 months.10
Tables 1–3 summarize the individual case-based data for 
cervical, ovarian, uterine and vaginal LCNEC, respectively.
Discussion
Neuroendocrine neoplasms of the gynecologic tract are 
particularly uncommon with NETs of the uterus or cervix 
representing 0.9% to 1.5% of the tumors and accounting 
for 100 to 200 diagnoses yearly in the United States.11 
Furthermore, with the potential ambiguity surrounding 
the diagnostic criteria, some LCNEC cases may have been 
inaccurately classified as undifferentiated or poorly dif-
ferentiated adenocarcinoma. Large cell carcinomas of the 
gynecologic tract are especially aggressive, tend to recur, 
and there is limited data regarding the natural history, pro-
gression, and management of the disease. Due to the rare 
nature of the disease, it is challenging to determine an 
optimal therapy by utilizing randomized controlled trials, 
but it has been proposed that these patients could be 
treated similar to those with small-cell neuroendocrine 
carcinoma because of similar malignant potential and 
platinum sensitivity.12 For therapeutic intervention, a 
multi-modality approach should be undertaken.
For our review, the 104 unique cases of gynecologic 
LCNECs were positive for neuroendocrine markers, such 
as chromogranin A, CD56 and synaptophysin. Of the 45 
cases of LCNEC of the cervix, an abnormal screening 
Papanicolaou smear and vaginal bleeding were the most 
common reasons for presentation. For the majority of ovar-
ian LCNEC cases, abdominal pain and/or abdominal dis-
tention were the reasons for presentation, whereas 
post-menopausal bleeding was the most common reason 
for presentation for endometrial and uterine LCNEC. The 
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Table 3. Endometrial, uterine corpus and vaginal large cell neuroendocrine carcinoma reported in the literature.
Origin (plus 
associated cells)
Presentation Age Stage Surgery Treatment Response 
(duration)
Authors 
(Reference)
Endometrium –  
Pure
Postmenopausal 
vaginal bleeding
71 IVB RH, BSO, OMY, 
PPALD
NFT DOD (1 months) Nguyen et al.5
Endometrium – 
Sarcomatoid
Abnormal 
uterine bleeding
40 IB TAH, BSO, 
OMY, PLD
NFT AWD (16 months) Terada54
Endometrium –  
Pure
N/A 50 IIIC TAH, BSO, 
OMY
RT, cisplatin, etoposide AWD (12 months) Mulvany55
Endometrium – 
Endometroid
N/A 80 IC TAH, BSO NFT DOD (5 months) Mulvany55
Endometrium – 
Endometroid
N/A 77 IIB TAH, BSO RT DOD (23 months) Mulvany55
Endometrium – 
Endometroid
N/A 79 IIIA TAH, BSO, 
Omental biopsy
RT AWD (2 months) Mulvany55
Endometrium – 
Endometroid
N/A 88 IIIC TAH, BSO, LN 
biopsy
RT AWD (1 months) Mulvany55
Endometrium Abdominal 
distention
73 IVB None Patient refused DOD (1 months) Makihara34
Endometrium Vaginal bleeding 73 IIIC TAH, BSO, 
OMY, PPALD
Cisplatin + irinotecan AWD (13 months) Makihara34
Endometrium Postmenopausal 
bleeding
59 IV TAH, BSO, 
OMY, PPALD
Carboplatin + paclitaxel 
with RT and 
brachytherapy;
DOD (12 months) Shahabi et al.4
 THEN: Pegylated 
doxorubicin followed 
by etoposide, cisplatin 
and LAR
 
Endometrium –  
Pure
Post-menopausal 
bleeding
70 IB TAH, BSO, 
OMY
Cisplatin + etoposide NED (6 months) Deodhar56
Endometrium –  
Pure
N/A 42 IC RH Cisplatin + etoposide AWD (9 months) Albores-
Saavedra et al.3
Uterine  
Corpus – Pure
Lower 
abdominal pain
52 IIIC2 TAH, BSO, 
PPALD
INITIAL: 
Irinotecan + cisplatin 
with RT
DOD (10 months) Kobayashi 
et al24
 PROGRESSION: RT, 
paclitaxel + carboplatin
 
Vagina Pelvic pain and 
difficulty voiding
53 IV None Palliative 
radiation + chemo
AWD (12 months) Jin et al.10
AWD: alive with disease; BSO: bilateral salpingo-oophorectomy; Chemo: chemotherapy; DOD: dead of disease; LAR: long acting-release 
octreotide; LN: lymph node; N/A: not available; NED: no evidence of disease; NFT: no further treatment; OMY: omenectomy; PLD: pelvic lymph 
node dissection; PPALD: pelvic and para-aortic lymph node dissection; RH: radical hysterectomy; RT: radiation therapy; TAH: total abdominal 
hysterectomy.
one case of LCNEC of the vagina reported by Jin et al. was 
of a 53-year-old female who presented with metastatic 
stage IV disease.10
LCNEC of the gynecologic tract has a poor prognosis, 
especially for patients that present in an advanced stage. A 
variety of therapeutic regimens exist with attention toward a 
multimodality approach, including combinations of surgery, 
chemotherapy and radiation. This multimodal approach is 
supported by both the Society of Gynecologic Oncology 
and the Gynecologic Cancer Intergroup.13 Survival outcome 
is variable and dependent on both stage at diagnosis and 
response to the treatment. Embry et al. reported that earlier 
stage (p < 0.00001) and the addition of chemotherapy (p = 
0.04) were associated with improved survival for cervical 
LCNECs.14 They also reported platinum agents (p = 0.034) 
and platinum+etoposide (p = 0.027) were associated with 
improved survival.14 Furthermore, for LCNECs with meta-
static lesions, long-term survival is uncommon.15 Because 
of the rarity of these malignancies, management is often 
extrapolated from small and large cell carcinomas of the 
lung. Adjuvant chemotherapy with cisplatin, carboplatin, 
etoposide or cyclophosphamide has been used in the man-
agement of LCNEC of the lung, and is very frequently used 
in LCNEC of the gynecologic tract as well.4
8 Rare Tumors
Cervix
Our 45 cases of cervical LCNEC summarized in Table 1 
include patients with all stages of disease as well as a wide 
range of survival (0.5 months to 151 months). Treatment 
included surgery, chemotherapy, and/or radiation, with a 
majority (76%) receiving surgery. Of note, Embry et al. 
reported 62 cases of cervical LCNEC; importantly, the 
authors documented a similar median age to ours (37 years) 
with the identical age range of 21 to 75. Furthermore, a 
majority of their patients also had stage I disease. Of these 
cases, 73% underwent primary surgery, 4.7% underwent 
primary radiation, 4.7% underwent chemotherapy and 8% 
had chemoradiation. There were 9.6% with no primary 
treatment. Reported patient outcomes were as follows: 
58% died of disease, 26% had no evidence of disease, 3% 
were alive with disease and 13% had no survival data. 
Multivariate analysis revealed that earlier stage (p < 
0.00001) and the addition of chemotherapy (p = 0.04) 
particularly platinum agents (p = 0.034) and the 
platinum+etoposide combination (p = 0.027) were asso-
ciated with improved survival.14
For early stage cervical LCNEC, therapy should begin 
with radical hysterectomy, bilateral salpingo-oophorec-
tomy, and pelvic lymphadenectomy. Gilks et al. reported a 
case of a 36-year-old patient with stage I disease who had 
no evidence of it 36 months after a radical hysterectomy.16 
However, the current recommendation is to follow surgery 
with chemoradiation, cisplatin (platinum-based therapy) 
and etoposide.13 Of note, this therapy is based on regimens 
used in small cell lung cancer as there are no prospective 
phase II or phase III clinical trials evaluating anti-tumor 
efficacy in gynecologic LCNEC. However, prophylactic 
brain irradiation is not recommended in these patients as it 
is with small cell lung cancer.
For locally advanced disease in women with neuroendo-
crine carcinoma (stage IB2–IVA disease), concurrent chem-
radiation followed by additional chemotherapy with intent 
to cure should be the treatment plan. The ideal regimen is 
the same as that described above, with cisplatin and etopo-
side given on a 3-week cycle. Sato et al. implemented 
chemotherapy (specific therapy not identified) with con-
current radiation therapy after a total abdominal hysterec-
tomy and bilateral oophorectomy in a 31 to year-old patient 
with stage 1B disease; this patient was reported to be alive 
with disease at 151 months.17 For patients with no evidence 
of intraperitoneal spread and nodal metastatic burden, neo-
adjuvant chemotherapy with cisplatin and etoposide fol-
lowed by consolidation radiation therapy may be of some 
benefit.13 However, per our analysis, LCNEC remains a 
disease with poor prognosis, with a median OS of less than 
2 years.
Hormone receptor and growth factor receptor expres-
sion could have a role in predicting survival in cervical 
LCNEC. Tangjitgamol et al. performed this evaluation for 
cervical LCNEC and identified a significantly shorter OS 
in patients with a HER-2 neu negative status as compared 
to those with positive HER-2 neu tumors (median OS: 14.2 
vs 33.1 months), and a trend towards a worse OS in patients 
positive for epidermal growth factor receptor.8 The group 
concluded that the combination of negative HER-2 neu sta-
tus and positive epidermal growth factor receptor expres-
sion impaired OS.8
There is a potential role for targeted therapy in cervical 
LCNEC. Somatostatin receptors are profusely expressed in 
low-grade NETs, and some somatostatin receptor binding is 
generally observed in high-grade NEC. Hence targeted ther-
apy with octreotide, a somatostatin analog, could be explored 
as suggested by Shahabi et al. Potential mechanisms by 
which octreotide could inhibit tumor growth include inhibi-
tion of growth hormone secretion, such as IGF-1, inhibition 
of angiogenesis, and through direct action on the tumor.4 
Kajiwara et al. also proposed using octreotide to treat neu-
roendocrine tumors, since 3 out of 7 cases (2 of 5 small cell 
carcinomas and 1 of 2 LCNEC) expressed somatostatin 
receptor type 2A.18 However, a larger study is needed to vali-
date these conclusions. Many clinicians are skeptical of the 
role for somatostatin analog in LCNEC management.
The role of radiation therapy should be strongly consid-
ered, especially with the addition of brachytherapy in the 
setting of LCNEC of the cervix. Robin et al. found a sig-
nificant improvement in OS when brachytherapy and exter-
nal beam radiation therapy were combined. They identified 
100 patients with locally advanced non-metastatic neuroen-
docrine cervical cancer (included both large cell and small 
cell) that were treated with definitive chemoradiotherapy 
between 2004 and 2012. There was a substantial improve-
ment in OS when brachytherapy was administered in addi-
tion to external beam radiotherapy. By multivariate 
analysis, an improved median survival of 48.6 versus 
21.6 months (95% CI, 0.255–0.883; p = 0.019) was seen 
with the addition of brachytherapy compared to external 
beam radiotherapy alone. This study was performed in 
patients with locally advanced neuroendocrine carcinoma 
of the cervix, of both large and small cell etiology, treated 
with chemoradiotherapy.19
Ovary
As evidenced by our 45 cases of ovarian LCNEC summa-
rized in Table 2, patients with this disease unfortunately 
have a poor prognosis; 8 month survival was noted for 
those patients with both stage III and stage IV disease. 
Reported survival for all stages ranged from 0 to 68 months. 
In the 33 cases reported by Oshita et al., the 5-year survival 
was only 34.9%.9 One case exhibited rapid disease progres-
sion with pelvic mass formation, liver metastasis and pelvic 
lymphadenopathy within 2 weeks after primary surgery, 
with the tumor being unresponsive to Taxol and carboplatin 
chemotherapy.9 Evidence that ovarian LCNEC is an 
Burkeen et al. 9
aggressive malignancy has also been reported in other cases 
outlined above.20,21 However, it is worth noting that there is 
evidence of success with surgery followed by adjuvant 
platinum-based chemotherapy. Dundr et al. reported a case 
of a 73-year-old with stage IV ovarian LCNEC and no evi-
dence of the disease 12 months after undergoing surgery 
and chemotherapy with carboplatin and paclitaxel.22 An 
anecdotal case series from MD Anderson Cancer Center 
reported 22 to 68 months survival in three stage I cases with 
standard surgery followed by adjuvant platinum-based 
chemotherapy.23 Based on the above-mentioned observa-
tions, therapeutic consideration similar to primary lung 
LCNEC can be applied toward those of ovarian origin. This 
includes utilizing such regimens as cisplatin/vinorelbine, 
cisplatin/etoposide, cisplatin/vinblastine, cisplatin/gemcit-
abine and cisplatin/docetaxel in tumors that are initially 
unresponsive to first line taxotere and cyclophosphamide 
therapy.9 In one case reported by Oshita et al., radiation was 
utilized for brain metastasis and the patient had no evidence 
of the disease for 64 months, which adds support to employ-
ing radiation in situations of local recurrence or distant 
metastasis.9
Uterus
Limited data exists to guide therapy in cases of uterine 
LCNEC, however as mentioned above, a multi-modality 
approach is commonly applied. Similar to LCNEC of the 
cervix, tumors in the uterus, notably the endometrium, are 
managed initially with cytoreductive surgery. Based on 
prior published reports, a hysterectomy and bilateral 
salpingo-ophorectomy are recommended at minimum.5 
Unfortunately, a number of cases were reported with 
early-stage disease at the time of surgery that developed 
distant metastasis or rapid recurrence; therefore, omentec-
tomy and pelvic and paraaortic lymphadenectomy should 
be considered for accurate staging. Of note, physicians 
may want to determine a patient’s response to chemother-
apy prior to initiating surgery, as surgery has often been 
shown to be of little benefit. Currently there is no consen-
sus regarding optimal management of these tumors after 
surgery. In the case reports as described, adjuvant chemo-
therapy and/or radiation was either performed or planned 
in the majority of the cases. Chemotherapy, radiation or 
both is favored by most treating physicians. Occasionally, 
neoadjuvant therapy is considered in cases where LCNEC 
is diagnosed on a preoperative curettage, or when an 
endometrial biopsy specimen is done in advanced cases of 
ovarian cancer. Adjuvant chemotherapy generally con-
sists of platinum and etoposide based chemotherapy as in 
cervical disease.5 Shahabi et al. incorporated octreotide 
into their treatment regimen due to a single case report of 
its use for an endometrial small cell NET in which a par-
tial response was reported; however, disease progression 
was observed.4 In the one case of LCNEC of the uterine 
corpus, Kobayashi et al. reported a rapidly progressing 
stage III disease that did not respond to irinotecan/cispl-
atin initially but paclitaxel/carboplatin with concurrent 
radiation was helpful.24
Conclusion
As discussed above, LCNECs are high-grade neuroendo-
crine carcinomas and represent a rare diagnosis, especially 
in sites such as the gynecologic tract. Our current under-
standing of the biology of this pathology is limited. As 
inadequate data exists regarding the treatment of this 
pathology, it has been demonstrated in the aforementioned 
cases of LCNEC in the gynecologic tract that a multimo-
dality treatment approach including surgery, chemotherapy 
and radiation should be undertaken. Further efforts are 
required to gain more knowledge on how best to treat these 
aggressive malignancies.
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